Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

Lantern Pharma

14/08/2026 13:25

Lantern Pharma Inc LTRN.OQ reported a quarterly adjusted loss of 57 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -40 cents.  The lone analyst forecast for the quarter was for a loss of 38 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Lantern Pharma Inc's reported EPS for the quarter was a loss of 57 cents​.
The company reported a quarterly loss of $7.07 million.
Lantern Pharma Inc shares had fallen by 36.9% this quarter and lost 13.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Lantern Pharma Inc is $17.50, about 85% above its last closing price of $2.63
This summary was machine generated from LSEG data August 14 at 12:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.38
-0.57
Missed
Mar. 31 2026 
-0.36
-0.30
Beat
Dec. 31 2025 
-0.46
-0.36
Beat
Sep. 30 2025 
-0.47
-0.39
Beat